Tandem Diabetes Care, Inc. (TNDM) Set to Announce Earnings on Monday
Tandem Diabetes Care, Inc. (NASDAQ:TNDM) is set to release its earnings data after the market closes on Monday, October 30th. Analysts expect Tandem Diabetes Care to post earnings of ($0.44) per share for the quarter.
Tandem Diabetes Care (NASDAQ:TNDM) last released its quarterly earnings results on Thursday, July 27th. The medical device company reported ($4.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($4.80) by $0.40. The company had revenue of $21.30 million for the quarter, compared to analysts’ expectations of $21.74 million. Tandem Diabetes Care had a negative return on equity of 1,177.11% and a negative net margin of 110.70%. The business’s quarterly revenue was down 7.4% compared to the same quarter last year. During the same period in the previous year, the business posted ($6.00) earnings per share. On average, analysts expect Tandem Diabetes Care to post $-17.06 EPS for the current fiscal year and $-8.55 EPS for the next fiscal year.
Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) opened at 2.53 on Monday. The company’s market capitalization is $12.71 million. Tandem Diabetes Care, Inc. has a 12-month low of $2.27 and a 12-month high of $70.00. The stock’s 50 day moving average price is $5.75 and its 200 day moving average price is $7.45.
In related news, CEO Kim D. Blickenstaff purchased 285,700 shares of Tandem Diabetes Care stock in a transaction that occurred on Friday, October 13th. The shares were acquired at an average cost of $3.50 per share, for a total transaction of $999,950.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.90% of the stock is owned by company insiders.
An institutional investor recently raised its position in Tandem Diabetes Care stock. Vanguard Group Inc. increased its stake in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 2.7% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,233,607 shares of the medical device company’s stock after acquiring an additional 32,991 shares during the quarter. Vanguard Group Inc. owned approximately 2.46% of Tandem Diabetes Care worth $987,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of equities analysts recently weighed in on TNDM shares. Piper Jaffray Companies reissued a “hold” rating and set a $15.00 price objective on shares of Tandem Diabetes Care in a report on Friday, October 6th. Zacks Investment Research cut Tandem Diabetes Care from a “buy” rating to a “hold” rating in a report on Tuesday, October 17th. Finally, Wedbush reissued an “outperform” rating and set a $17.00 price objective (down from $50.00) on shares of Tandem Diabetes Care in a report on Tuesday, October 10th. Six investment analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Tandem Diabetes Care presently has a consensus rating of “Hold” and a consensus price target of $29.31.
Tandem Diabetes Care Company Profile
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.